Diagnosis, therapeutic advances, and key recommendations for the management of factor X deficiency
| Autor: | Ri Liesner, Kaan Kavakli, Guenter Auerswald, Steven K. Austin, Flora Peyvandi, Carolyn M. Millar, María Teresa Álvarez Román |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Hemorrhage Disease Factor X deficiency Hemorrhagic Disorders 03 medical and health sciences 0302 clinical medicine Internal medicine Humans Medicine Disease management (health) Intensive care medicine Blood Coagulation Factor X Deficiency Coagulation Disorder Hematology business.industry Blood Coagulation Disorders Optimal management Oncology 030220 oncology & carcinogenesis Cryoprecipitate Fresh frozen plasma business 030215 immunology |
| Zdroj: | Blood Reviews. 50:100833 |
| ISSN: | 0268-960X |
| DOI: | 10.1016/j.blre.2021.100833 |
| Popis: | Factor X deficiency is a rare coagulation disorder that can be hereditary or acquired. The typology and severity of the associated bleeding symptoms are highly heterogeneous, adding to the difficulties of diagnosis and management. Evidence-based guidelines and reviews on factor X deficiency are generally limited to publications covering a range of rare bleeding disorders. Here we provide a comprehensive review of the literature on factor X deficiency, focusing on the hereditary form, and discuss the evolution in disease management and the evidence associated with available treatment options. Current recommendations advise clinicians to use single-factor replacement therapy for hereditary disease rather than multifactor therapies such as fresh frozen plasma, cryoprecipitate, and prothrombin complex concentrates. Consensus in treatment guidelines is still urgently needed to ensure optimal management of patients with factor X deficiency across the spectrum of disease severity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect